EverQuest EIS Fund.

EverQuest invests in enabling technologies and advanced manufacturing solutions. Its edge is a strategic partnership with CPI, giving the Fund a proprietary pipeline, independent technical validation and scale-up infrastructure a generalist EIS manager cannot replicate.

Key features of the EverQuest EIS Fund

• Track record. 20+ exits generating over £1billion of aggregate value at prior firms, including one above £1billion and two above £300m. Nuformix delivered a 14.3x return.
• Exit focus. Strategic acquisition pathways mapped before investment, with a five-year exit horizon targeted.
• Strong risk management. 5 write-offs in 50 investments over 25 years – 3.9% of invested capital, all in pre-clinical biology, a category the Deep MakeTech mandate now excludes.
• Deployment. 4-8 companies per subscription, targeted within 12 months. Advance Assurance obtained before investment; EIS3 typically 3–6 months.
• Origination. 300+ proprietary, largely off-market opportunities a year through CPI.
• Example of current holdings. Q5D Technology (5.4x at cost), DEScycle (2.3x) and Qkine (1.5x) – unrealised IPEV value.
• Recent deployment. FluoRok, an Oxford spin-out reinventing fluorination chemistry, backed in an oversubscribed £22m round alongside BGF, OSE and Volta.

Source: All data from EverQuest Capital Partners as at 31/08/2026.